A patient with atrial fibrillation on warfarin therapy who is prescribed ezetimibe should be monitored for which of the following symptoms?

The correct choice relates to the need for monitoring for signs of bleeding, which is particularly important for a patient on warfarin therapy. Warfarin is an anticoagulant that increases the risk of bleeding. Ezetimibe is a cholesterol-lowering medication that, while not directly associated with increased risk of bleeding, can affect liver function and lipid metabolism.

In patients on warfarin, any additional factor that could contribute to bleeding risks or liver dysfunction must be closely watched. Blood in urine or stool is an important symptom indicating potential internal bleeding or gastrointestinal bleeding, which can be life-threatening. Therefore, monitoring for such symptoms in this context is critical to ensure the patient's safety while managing both their atrial fibrillation and hyperlipidemia effectively.

In contrast, yellowing of the skin may imply liver dysfunction, which would also warrant attention but is less specific to the use of both drugs together. Blurred vision and abdominal pain, while they could indicate other conditions, are not directly related to the co-administration of warfarin and ezetimibe in terms of monitoring for bleeding complications.